000102211 001__ 102211 000102211 005__ 20220908120515.0 000102211 0247_ $$2doi$$a10.1016/j.ctarc.2021.100355 000102211 0248_ $$2sideral$$a124382 000102211 037__ $$aART-2021-124382 000102211 041__ $$aeng 000102211 100__ $$aAl-Wasaby, S. 000102211 245__ $$aIn vivo potential of recombinant granulysin against human melanoma 000102211 260__ $$c2021 000102211 5060_ $$aAccess copy available to the general public$$fUnrestricted 000102211 5203_ $$a9-kDa granulysin is a protein expressed into the granules of human cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. It has been shown to exert cytolysis on microbes and tumors. We showed previously that 9-kDa granulysin exerted cell death by apoptosis in vitro on hematological tumor cell lines and also on cells from B-cell chronic lymphocytic leukemia (B-CLL) patients. In addition, we have shown the anti-tumor efficiency of granulysin as a single agent in two in vivo models of human tumor development in athymic mice, the MDA-MB-231 mammary adenocarcinoma and the NCI-H929 multiple myeloma, without signs of overt secondary effects by itself. In this work, we have tested recombinant 9-kDa granulysin in an in vivo and especially aggressive model of melanoma development, xenografted UACC62 cells in athymic mice. Recombinant granulysin was administered once UACC62-derived tumors were detectable and it substantially retarded the in vivo development of this aggressive tumor. We could also detect apoptosis induction and increased NK cell infiltration inside granulysin-treated tumor tissues. These observations are especially interesting given the possibility of treating melanoma by intra-tumor injection. 000102211 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B31-17R$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R 000102211 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000102211 592__ $$a0.52$$b2021 000102211 594__ $$a1.5$$b2021 000102211 593__ $$aOncology$$c2021$$dQ3 000102211 593__ $$aCancer Research$$c2021$$dQ3 000102211 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000102211 700__ $$0(orcid)0000-0002-1657-4792$$aGuerrero-Ochoa, P.$$uUniversidad de Zaragoza 000102211 700__ $$aIbáñez-Pérez, R.$$uUniversidad de Zaragoza 000102211 700__ $$aSoler, R.$$uUniversidad de Zaragoza 000102211 700__ $$0(orcid)0000-0003-4115-9766$$aConde, B.$$uUniversidad de Zaragoza 000102211 700__ $$0(orcid)0000-0003-3043-147X$$aMartínez-Lostao, L.$$uUniversidad de Zaragoza 000102211 700__ $$0(orcid)0000-0002-5175-8394$$aAnel, A.$$uUniversidad de Zaragoza 000102211 7102_ $$11003$$2443$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Histología 000102211 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología 000102211 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000102211 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular 000102211 773__ $$g27 (2021), 100355 [7 pp.]$$tCancer Treatment and Research Communications$$x2468-2942 000102211 8564_ $$s7920905$$uhttps://zaguan.unizar.es/record/102211/files/texto_completo.pdf$$yVersión publicada 000102211 8564_ $$s2558529$$uhttps://zaguan.unizar.es/record/102211/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000102211 909CO $$ooai:zaguan.unizar.es:102211$$particulos$$pdriver 000102211 951__ $$a2022-09-08-11:54:50 000102211 980__ $$aARTICLE